PRF Technologies (PRFX) Income from Continuing Operations (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Income from Continuing Operations of 7600000.0 for Q2 2024, down 204.12% year-on-year from 7299154.5 in Q3 2023, and down 30.63% on a QoQ basis from 5818000.0 in Q1 2024.
PRF Technologies (PRFX) Income from Continuing Operations (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Income from Continuing Operations for 5 consecutive years, with 7600000.0 the latest figure, recorded in Q2 2024.
- Quarterly Income from Continuing Operations fell 204.12% year-over-year to 7600000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 7600000.0 (down 204.12% YoY) and the FY2025 annual result came in at 5022000.0, up 66.16% from the prior year.
- Income from Continuing Operations slipped to 7600000.0 in Q2 2024 per PRFX's latest filing, from 5818000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PRFX reached as high as 132000.0 in Q1 2020 and fell as low as 10740000.0 in Q4 2023.
- A 5-year average of 3571611.11 and a median of 2294000.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations sank 1606.06% — and 2023, when it soared 31.46%.
- Year by year, Income from Continuing Operations stood at 4167000.0 in 2020, then sank by 65.42% to 6893000.0 in 2021, then decreased by 28.75% to 8875000.0 in 2022, then retreated by 21.01% to 10740000.0 in 2023, then rose by 29.24% to 7600000.0 in 2024.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 7600000.0, 5818000.0, and 10740000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7.60 Mn |
| Mar 31, 2024 | -5.82 Mn |
| Dec 31, 2023 | -10.74 Mn |
| Sep 30, 2023 | -1.60 Mn |
| Jun 30, 2023 | -2.50 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Sep 30, 2022 | -2.34 Mn |
| Jun 30, 2022 | -2.08 Mn |
| Mar 31, 2022 | -1.91 Mn |
| Dec 31, 2021 | -6.89 Mn |
| Sep 30, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.88 Mn |
| Mar 31, 2021 | -2.25 Mn |
| Dec 31, 2020 | -4.17 Mn |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | -148,000.00 |
| Mar 31, 2020 | -132,000.00 |